BRCA1-mutant thymoma and the role of PARP inhibitors: a case report
Authors:
- Joey Yan Leng TanJTJoey Yan Leng Tan
- Jeanette YuenJYJeanette Yuen
- Joanne NgeowJNJoanne Ngeow
- Chay Wen YeeCYChay Wen Yee
- Francis Hong Xin YapFYFrancis Hong Xin Yap
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- BRCA and Beyond: Impact on Therapeutic Choices Across CancerCancers, 2024
- Risk factors for the failure of first‐line PARP inhibitor maintenance therapy in patients with advanced ovarian cancer: Gynecologic Oncology Research Investigators Collaboration Study (GORILLA‐3004)Cancer Medicine, 2023
- Genomic characterization of thymic epithelial tumors in a real-world datasetESMO Open, 2023
- The therapeutic relevance of a BRCA2 mutation in a patient with recurrent thymoma: a case reportMediastinum, 2022
- Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic LethalityCancers, 2022
- Metastatic Thymoma Harboring a Deleterious BRCA2 Mutation Derives Durable Clinical Benefit from OlaparibThe Oncologist, 2019
- Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapyNature Reviews Clinical Oncology, 2019
- Tumour lineage shapes BRCA-mediated phenotypesNature, 2019
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian CancerNew England Journal of Medicine, 2018
- Mutations of epigenetic regulatory genes are common in thymic carcinomasScientific Reports, 2014